Longboard Pharmaceuticals, Inc.

18.52 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Longboard Pharmaceuticals, Inc. stock is down -10.49% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc. focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.

  • B. Riley
    Tue Jun 11, 14:44
  • HC Wainwright & Co.
    Tue Jun 11, 13:25